Therapeutic area
  • Cancer

What the technology does

Polymerase with enhanced ability to process bisulphite-treated DNA and hydrophobic base analogues.

Advantage

Compared to the standard enzyme of choice (Taq), polymerase 5D4 has enhanced DNA synthesis efficiency on bisulphite-treated DNA and enhanced bypass of dhU6S adducts in bisulphite-treated non-desulphonated DNA. It also has improved sensitivity in PCR amplification of bisulphite-treated DNA or uracil-containing DNA templates in general.

Main application field

Polymerase 5D4 has utility in bi-sulphite sequencing and in processing of uracil-containing DNA templates. It was originally selected for its ability to process hydrophobic base analogues, so would have wider application in this field

Usage

R&D tool

Status

Technology ready for evaluation and licensing

Intellectual Property

Granted patents include EP2145956 and US9096835.

Offering

Non-exclusive licence

Key Contact

  • In submitting your personal data via this form, you consent to being contacted via the details provided so that your enquiry can be responded to. A backup of your data will be held but only authorised individuals will be able to access your data. If you would like your data to be removed, please email support@thewebkitchen.co.uk.
    Please see our Privacy policy in relation to the personal data you submit to us through this page.
  • We would love to send you information about LifeArc news and events. Please let us know if you would like us to contact you by selecting one of the following options:
All Licensing Opportunities